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Pregnancy and malignant 
diseases — principles of management 
ABSTRACT
Pregnancy-associated malignant diseases introduce multiple dilemmas to the multidisciplinary boards, related 
to both the oncological treatment as well as to obstetrical management. The most frequent oncological diseases 
diagnosed during pregnancy are breast cancer, oncohematological conditions, uterine cervix cancer and skin 
cancers. There are different clinical scenarios: interruption of the pregnancy and further use of the most appro-
priate oncological strategy; it is also possible to postpone the oncological treatment for the postpartum period 
with a watch-and-wait strategy until the foetus is mature and the delivery is planned. The third scenario includes 
concurrent treatment of both conditions: use of chemotherapy, radiotherapy and surgery during an ongoing preg-
nancy. Choosing among these scenarios is considering many factors, including type and stage of the malignant 
tumour, pregnancy term, desire and informed decision of the pregnant woman to keep or interrupt the pregnancy. 
The current review is focused on the basic principles of the oncological modalities (surgery, chemotherapy and 
radiotherapy) during pregnancy as well as their influence over the pregnant woman and the foetus, over the 
obstetrical management and the timing and mode of delivery, delivery anaesthesia, lactation and breastfeeding 
from the point of view of the evidence-based medicine.
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Introduction
Pregnancy and neoplasia are a rare combination 
and thus evidence-based data and recommendations 
are limited [1]. In such a situation, the care for the 
mother and the foetus, the obstetrical and the onco-
logical management should run in parallel, which may 
be rather challenging. The diagnosis of “cancer during 
pregnancy” introduces not only medical but many other 
problems, including ethical, personal, religious or even 
legal issues. Every cancer, diagnosed during pregnancy, 
qualifies the pregnancy as high-risk and thus the woman 
should be taken care of in specialized centres with expe-
rience both in oncology and obstetrics [2, 3]. It is known 
that the pregnancy itself does not worsen the oncological 
prognosis, but both the mother and the foetus may be 
susceptible to potential side effects of the different on-
cological treatments. Potential obstetrical complications 
include but are not only limited to intrauterine retarda-
tion of the foetus, preterm delivery with the delivery of 
an immature or small for the gestational age foetus. [1–4]
Epidemiology
 — The rate of cancer during pregnancy is reported 
between 17–25/100,000 pregnancies [1].
 — The most frequent neoplasia are:
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1. breast cancer,
2. oncohematological diseases (lymphomas, leu-
kaemia), 
3. uterine cervix cancer,
4. skin cancers (basocellular, melanoma) [1].
Obstetrical therapeutic options 
Obstetrical management depends on many patient-, 
foetus- and cancer-related factors, but treatment deci-
sions most frequently take into consideration:
 — cancer type,
 — cancer disease stage,
 — gestational age of the foetus (correctly determined) 
with screening for malformations) 
 — (lack of) Desire to keep the pregnancy [1–4] 
The obstetrical management may be divided into:
1. Interruption of the pregnancy before the time 
when the foetus would capable of life [< 24th ges-
tational week (g.w.)]. This is a relevant strategy in 
aggressive rapidly progressive cancers with poor 
prognosis, especially if diagnosed in the early 
weeks or months of the pregnancy.
2. Delay of the oncological treatment until the 
second trimester of the pregnancy in case of 
diagnosis in the first trimester (except for some 
haematological malignancies).
3. Oncological treatment during pregnancy. 
The oncological treatment is multimodal and 
consists of different therapeutic strategies, 
including surgery, chemotherapy and/or radio-
therapy. They may be delivered in a different 
sequence given both the term of the pregnancy 
and the type and stage of the oncological disease.
4. Delay of the oncological treatment until after 
delivery. All modalities of the complex anticancer 
treatment or only some of them could be post-
poned, depending on the stage of the oncological 
disease, the possibility to deliver the treatment 
during pregnancy and the age of the pregnancy. 
This is another potential clinical scenario, con-
sidered in cases of a diagnosis of cancer close to 
the expected date of delivery [1].
Factors, influencing the treatment 
decisions in cancer during pregnancy
The general pregnancy and cancer management 
principles are related to the following aspects:
1.  Cancer-related factors — oncological charac-
teristics as a stage of the disease, histological 
type and potential treatment options. These 
determine the indications for anticancer manage-
ment as well as the use of one or more treatment 
modalities (surgery, chemo- or targeted ther-
apy, radiotherapy, etc.). The most appropriate 
treatment sequence is also crucial and may be 
modified by other non-cancer related factors. 
2.  Foetus-related factors — the age of the foetus 
and the stage of development and the degree 
of maturation are crucial. It strongly influences 
anticancer treatment choices as potential neona-
tal issues may develop as a consequence of the 
anticancer treatment. 
3.  Mother-related factors — treatment decisions 
are the priority of the pregnant woman and her 
family. Besides the decision to keep or not the 
pregnancy or the possibility for further pregnan-
cies, the health status of the mother is essential 
when planning the anticancer treatment. Po-
tential obstetrical issues and mode of delivery 
(Caesarean section versus vaginal delivery) are 
also considered, aiming at the most precise as 
a possible prediction of the time of delivery. 
Obstetrical factors are roughly summarized as: 
•  time of delivery and choice of mode of deliv-
ery (vaginal versus Caesarean section),
•  anaesthesia during delivery (general ver-
sus local),
•  histological examination of the placenta,
•  breastfeeding and lactation [1].
Anticancer treatment during pregnancy 
— general principles
The oncological treatment is complex and consists 
most frequently of a multimodal approach. Systemic 
chemotherapy, radiotherapy or surgery may be used 
in sequence or different combinations and sequences.
Principles of surgery during pregnancy
General statements
Surgery is safe for the foetus after the first trimester. 
If the condition of the pregnant woman and the stage 
of the oncological disease permit, it is recommended to 
delay surgery until after delivery; it could also be done 
during delivery with an elective Caesarean section. 
Regional anaesthesia techniques are given preference 
over general anaesthesia [5].
Physiological changes, related to pregnancy and 
modifying the surgical process
Some physiological changes in the body of the 
mother are typical for the pregnancy period and may be 
relevant in the case of cancer during pregnancy. Between 
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the 6th and 34th g.w. the extracellular liquid increases 
with 3–4 litres due to the antidiuretic hormone (ADH) 
and the renin-angiotensin-aldosterone system (RAAS). 
This leads to haemodilution, a drop in the haemoglobin, 
haematocrit and albumin levels and the pharmacokinet-
ics is therefore changed [6]. Additionally, the enlarge-
ment of the uterus and the increase of the pressure over 
the abdominal organs may lead to the development 
of gastroesophageal reflux with subsequent risk of 
aspiration syndrome, most frequently during the third 
trimester. Moreover, the pregnancy increases the throm-
bogenic risk as the coagulation factors VII, VIII, IX, X, 
XII and the plasminogen are in increased levels. The 
thromboembolic risk may be additionally increased due 
to venous stasis in the lower extremities or the neoplastic 
process itself. The postoperative immobilization with the 
damage of the vascular endothelium leads to the libera-
tion of inflammatory mediators and may also increase 
the thrombogenic risk [1, 5].
Recommendations for surgery during pregnancy
 — Recommendations for preoperative care
 Conditions as diabetes, hypertension and medication 
intake should also be considered, compensated, con-
trolled and if needed — corrected. The ultrasound 
examination with a record of the foetal heart sounds 
under obstetrical monitoring are safe, providing in-
formation for the foetal development and the actual 
status of the foetus. Corticosteroids (CS) may be 
prescribed in cases of risk for preterm delivery [5].
 — Recommendations for intraoperative care 
 Interventions between 3rd and 5th g.w. should be 
avoided if possible due to a risk of defects in the 
neural tube. In case of surgery, the pregnant woman 
should be positioned in the left lying position after 
the 20th gestational week (not to compress the v. 
cava and to overload the heart). The risk of aspi-
ration increases in the position of Trendelenburg 
(especially during laparoscopic procedures). Hemo-
dynamic stability should be observed — hypotonia 
should be avoided, which could lead to a drop in the 
uteroplacental blood transfer, especially in foetal 
distress. The abdominal surgery could be planned 
for the second trimester when the risk of abortion is 
low, and the size of the uterus permits an adequate 
approach to the abdomen. A laparoscopic approach 
is not routinely recommended later than 26–28 g.w. 
The risks in laparoscopy are the development 
of hypercapnia, decreased blood flow due to the 
pneumoperitoneum and aspiration syndrome. The 
recommendations for the laparoscopic procedure, 
in case it should be done, include its performance 
by an experienced surgeon with a duration of the 
procedure less than 90 minutes, intraabdominal 
pressure 10–13 mm Hg; open approach for the first 
trocar, monitoring of the foetal heart sounds via 
cardiotocography and avoidance of intraprocedural 
hypotension [5, 7, 8].
 — Recommendations for postoperative care
 In postoperative care, an assessment of the foetal 
condition via ultrasound and obstetrical moni-
toring should be carefully performed. The pain 
control should be done via paracetamol, trama-
dol or NSAIDs. The use of these drugs during the 
3rd trimester should be avoided as in 50–80% they 
may induce a preterm closure of the arteriosus duct 
with subsequent pulmonary hypertension. Prophy-
lactic use of low-molecular heparin is mandatory in 
the postoperative period [9–11].
 The risks in surgery during pregnancy are in general 
related to potential postoperative infections, that 
may induce preterm rupture of the foetal sac, which 
may subsequently induce foetal death, respiratory 
distress syndrome, need of mechanical ventilation, 
intraventricular haemorrhages or necrotic entero-
colitis. In risk of preterm delivery, tocolytics are 
recommended to delay the delivery for 48 hours 
with the use of corticosteroids for stimulation of the 
foetal lungs’ maturation [1, 3].
Principles of chemotherapy during pregnancy
Table 1 summarizes the main effects of chemo-
therapy on embryo and foetus development [12]. 
A. It cannot be done during the first trimester [1].
B. Chemotherapy, if used during the implantation peri-
od leads to the “all or nothing” phenomenon. It may 
cause malformations if used during days 10 to 56 of 
the pregnancy which the organogenesis period. This 
is the reason why chemotherapy treatment should 
not be used before 14th g.w. It should not be used 
after the 35th g.w. because chemotherapy can lead 
to neutropenia which increases the risk for infection 
of the mother and the baby [13, 14].
C. The risks for the foetus are intrauterine foetal re-
tardation, preterm delivery, immaturity, neonatal 
toxicity — suppression of the bone marrow. This 
is the reason to recommend a minimum 3-weeks 
interval between chemotherapy and the expected 
time of delivery [15–18]. It is thus not routinely rec-
ommended to give chemotherapy after the 35th g.w.
D. The risk for the pregnant woman is of potential 
haematopoiesis suppression with further infections, 
bleeding or anaemia risks [19, 20].
E. Long-term (delayed) consequences over the foetus 
due to exposure to chemotherapy during their intrau-
terine foetal life. This is the reason to forbid the use 
of some target or cytotoxic agents (e.g., trastuzumab, 
bevacizumab, platinum salts, methotrexate, etc.).
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Endocrine therapy is contraindicated during preg-
nancy especially in breast cancer because is teratogenic 
and has been associated with birth defects in children of 
women who inadvertently have utilized the treatment 
during pregnancy [21, 22].
The incorporation of immunotherapy into clinical 
practice during pregnancy is recent and there is no 
sufficient data to speculate about their security in hu-
mans. For the time being, the utilization of these drugs 
during pregnancy is not recommended [23]. In animal 
models, anti-PD-1/PD-L1 and anti-CTLA-4 inhibitors 
during pregnancy are associated with an increase in 
abortion rates, stillbirths, premature delivery and higher 
incidence of infant mortality, especially when utilized 
during the third trimester [24–27].
Molecularly targeted agents are increasingly being 
used in modern oncology practice.[23] Most of these 
drugs are considered new in the practice and have no col-
lected data of their effects while using during pregnancy. 
Imatinib increases the risk of spontaneous abortion and 
major malformations — exencephaly, encephalopathies 
and abnormalities in the skull bones. [23]. Trastuzumab 
is associated with oligohydramnios. Bevacizumab causes 
hypertension and proteinuria and it is assumed hypoth-
esized that it might induce pre-eclampsia. Rituximab 
can cause immunosuppression by B-cell depletion in 
neonates [28].
 — Neurocognitive development and results at school. 
There are several trials on this topic. A trial of Hahn 
(2006) on 40 children of age 2 months to 13 years 
reports one case of Dawn syndrome and 1 case of 
syndrome of deficit of attention [29]. In 70 children 
of age 1,5 to 17,6 years, Amant (2012) reports 2 cases 
with development of mental retardation but they 
are considered to be due to foetal immaturity [30]. 
The same author in 2015 reports poor cognitive 
results in 96 children of age 1.5–3 years that is also 
related to their prematurity in comparison non-ex-
posed to the chemotherapy control group [31]. 
A study by Cardonick (2012) does not find a sig-
nificant difference in cognitive development in 
35 children of age 1,5 to 10,4 years in comparison 
with healthy controls [32].
 — Behavioural changes (depression, anxiety, aggres-
sion or issues with the discipline). There are 2 studies 
with data on this topic: Amant (2012) reports 29% 
of such behavioural changes in 6 of 21 children of 
age 5–16 years. [29] Cardonick (2015) reports 23% 
cognitive issues (8 out of 35 children) in the exposed 
to chemotherapy group of children in comparison 
with 18 % (4 out of 22) in the control group [33].
Future trials are needed to study the long-term ef-
fects of chemotherapy on foetal fertility or the rates of 
secondary cancers. 
Some non-antineoplastic medications which are 
widely used in oncology practice as supportive care also 
can be a cause of concern during pregnancy.
Bisphosphonates are generally contraindicated 
in pregnancy because they may reduce the calcium 
delivered to the foetus and induce skeletal malfor-
mations (reduced bone growth), low birth weight 
[34–36]. The granulocyte colony stimulation fac-
tors (GCS-F) can be used only in cases of severe 
neutropenia. In animal studies is observed that the 
use of GCS-F during the pregnancy can increase 
the spontaneous abortion rate and low birth weight 
with no increase in malformations. There is no such 
observation in human [37].
Table 1. The main effects of chemotherapy during pregnancy on embryo and foetus development [12]
Period of 
pregnancy
Impact on embryo or fetus Impact on the perinatal 
period
Long-term impact
First 4 weeks Either pregnancy loss or no adverse 
effect
Not known Not known
From 4 weeks to 
the end of  
1st trimester
Malformations in 7–17% of children 
born to mothers receiving a single 
drug or 25% in case of combination 
therapy
Not known Not known
Second or  
3rd trimester
Case reports of reversible fetal 
heart toxicity for treatment with 
anthracyclines, particulary when 
trastuzumab is associated in the 
regiment
Malformations are as frequent as  
in children barn to  healty mothers
Preterm delivery and low birth 
weight (11%)
Myelosuppression (1–43% 
according to time of 
therapy suspension)
In general neuropsychological 
development is not affected. When 
retard is demonstarated, it  is ascribed 
to prematurity
Older children frequently have 
internalzing behavioral problems 
Progressive left ventricular dysfunction 
several years afteranthracycline exposure
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Principles of radiotherapy during pregnancy —  
general recommendations
A. Malignant diseases, treated with radiotherapy (RT) 
—  treatment recommendations for use during preg-
nancy. In cases of breast cancer, RT could be delivered 
until 18–19 g.w. as there is enough distance of the 
irradiated area to the pregnant uterus. In cases of 
supradiaphragmatic lymphadenopathy, RT could also 
be delivered in e.g., lymphomas. In brain tumours or 
head and neck cancers RT could be delivered at any 
time during pregnancy whereas in the uterine cervix 
RT cannot be delivered as it induces foetal death [38].
B. The risks for the foetus during RT (foetal 
dose < 0.1 Gy) are: intrauterine retardation of 
the foetus (small for their gestational age, risk of 
cardiovascular or metabolic complications, malfor-
mities (3–8 g.w.), mental retardation (8–25 g.w) and 
secondary neoplasia — 0–38 g.w. (e.g., leukaemia or 
solid paediatric tumours) (Tab. 2) [1, 38].
The combination of pregnancy and oncologic 
diseases leads to some specific neonatal and obstetri-
cal problems.
The neonatal problems are due to the immaturity 
and/or the preterm delivery, both iatrogenic or as a re-
sult of intrauterine chemotherapy exposure. These are 
respiratory distress syndrome, temperature instability, 
excessive body weight loss, sepsis, hypoglycaemia, jaun-
dice, risk of neuro-behavioural problems (poor results 
at school, need of special additional education) [1, 2].
The obstetrical problems are related to time and 
mode of delivery, anaesthesia of delivery, histological 
assessment of the placenta, breastfeeding and lactation.
1. Time of delivery
 Efforts should be made not to permit delivery 
before 37th g.w. to avoid iatrogenic immaturity. 
If chemotherapy is delivered during pregnancy, 
its last cycle should be no later than 3 weeks of 
the expected date of delivery [4, 40–42] to allow 
foetal bone marrow recovery [6].
2. Delivery mode
 It is determined by obstetrical indications. Vagi-
nal delivery is the first method of choice and 
should be given priority due to the decreased 
blood loss, the shorter hospital stay and the lower 
risk of infections. The rates of elective Caesarean 
section in pregnant women with cancer is reported 
to be about 35% in the literature. There are some 
contraindications for vaginal delivery that should 
be considered: metastatic bone disease, brain 
metastases, uterine cervix cancer (the Caesarean 
sections aims at avoiding the trauma of the lower 
uterine segment) and vulvar cancer [1, 3].
3. Anaesthesia during delivery
 The gold standard for anaesthesia during and 
after delivery are the regional techniques: spinal 
or spinal-epidural anaesthesia. Contraindications 
to the regional anaesthesia may be brain tumours 
or metastases, metastatic bone disease, haemato-
logical neoplasia (e.g., acute leukaemia) due to 
the risk of hematoma and infection, leucopoenia 
and/or thrombocytopenia (risk of hematoma and 
infections) [1, 7].
4. Histological assessment of the placenta
 The histological assessment of the placenta is 
indicated in the search of metastases and most 
frequently these are registered in melanoma, 
lymphoma as well as in leukaemia [43].
5. Breastfeeding and lactation
 Chemotherapy during pregnancy leads to a de-
crease or interruption of lactogenesis. On the 
other hand, lactation during breastfeeding is 
not recommended as the cytostatics may be 
eliminated with the milk [13, 14, 41, 42]. Breast-
feeding is possible after breast surgery or RT to 
the breast [44].
Conclusion
The management in case of pregnancy-associated 
cancer has different treatment strategies: interruption of 
the pregnancy and starting the treatment, a delay of the 
treatment after delivery or starting the treatment during 
the pregnancy. The most frequent complications of the 
chemotherapy during pregnancy are related to preterm 
Table 2. Risks to the foetus of radiotherapy during pregnancy [39]
Gestational age (weeks) Risks
Preimplantation (1) Lethality
Organogenesis (2–7) Lethality, gross malformations, growth retardation, sterility, cataracts, other neuropathology, 
malignant disease
Early foetal (8–15) Lethality, gross malformations, growth retardation, mental retardation, sterility, cataracts, 
malignant disease
Mid foetal (16–25) Gross malformations, growth retardation, mental retardation, sterility, cataracts, malignant disease
Late foetal (> 25) Growth retardation, sterility, cataracts, malignant disease
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delivery risk as well as the risks, arising from the me-
tabolism of the cytostatics, which mandates if possible, 
prediction of the last chemotherapy cycle no later than 
3 weeks before the expected date of delivery. Surgical 
treatment and chemotherapy should be avoided before 
the 14th g.w. RT could be delivered as long as there is suf-
ficient distance of the irradiated field from the pregnant 
uterus. Laparoscopy could be considered before the 26th 
g.w., taking into consideration the increased risk of as-
piration and hypercapnia. The hemodynamic should be 
closely monitored during surgery and hypotonia should 
be rigorously avoided. Low molecular heparins are rec-
ommended in the postoperative setting and the foetus 
should be monitored via ultrasound and recording of the 
foetal heart sounds. During delivery, for the anaesthesia, 
local techniques should be given preference, whereas 
in the postoperative period, anaesthesia is given with 
analgesics. The mode of delivery is preferably vaginal. 
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